CIPP Rett Centre

 

The CIPP Rett Centre is a clinical treatment and research centre for children and adults with Rett Syndrome and related disorders of all ages.

Based at King’s College Hospital, the Centre monitors children and adults with Rett Syndrome and related disorders nationally through the CIPP Rett Database and conducts clinical trials.

The CIPP Rett Centre accepts referrals from a variety of sources. These include Consultants from various specialities (including paediatricians and neurologists), GPs, patient organisations and self-referrals. To refer a patient to the CIPP Rett Centre, email: [email protected]

or contact [email protected] for more info.

CIPP Rett Centre intervention is based on a holistic multi-modal approach. As part of the referral process, parents/carers will be asked to complete a battery of online questionnaires which will inform the acceptance and prioritisation of the referral. Local services are expected to be either involved or be willing to work within a Shared Care Protocol in order to optimise outcomes quickly.

 

CIPP Rett Database

The CIPP Rett Database is an online system through which the CIPP Rett team are able to monitor the well-being of UK patients with Rett Syndrome and related disorders at a distance.

Being part of the CIPP Rett Database is also a way of helping with efforts to bring about treatments for Rett Syndrome.

The more patients who are on the database, the more information the team is able to gather about Rett Syndrome, how it affects UK patients and the need for treatment.

You can add your child or adult with Rett Syndrome to the CIPP Rett Database by emailing: [email protected].

    Contact Details


     

    Any enquiries, please email [email protected]

    Latest news

    • Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

      Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

      On June 18th, Neurogene provided an update on the first “high dose” patient in
    • Taysha Announcement Key Takeaways

      Taysha Announcement Key Takeaways

      On June 18th, Taysha shared interim clinical data from the REVEAL Adolescent & Adult
    • Neurogene press release: NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program

      Neurogene press release: NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program

      On June 3rd, Neurogene announced that the FDA has chosen their Rett syndrome gene